Background: Paediatric data on CNS penetration of antiretroviral drugs are scarce.
Introduction
Since the introduction of combined ART (cART), the incidence of HIV encephalopathy in perinatally HIV-infected children has declined significantly from 30%-50% to ,2%.
1 Despite this, neurocognitive deficits with macro-and microstructural brain injury and signs of ongoing neuroinflammation remain present in HIV-infected children on long-term cART. [2] [3] [4] [5] [6] [7] Subtherapeutic drug concentrations in the CNS might play a role in HIV-related neurocognitive deficits in children. The bloodbrain barrier (BBB) effectively limits penetration of many toxins and drugs from the main circulation into the brain, but might be a challenge to overcome in the treatment of intracerebral infections. Based on the individual drug characteristics, antiretroviral (ARV) drugs penetrate into the CNS to a different extent. 8, 9 In adult patients, tenofovir has been shown to penetrate poorly into the CNS and did not reach the IC 50 in CSF in 77% of patients. 10 Efavirenz, on the other hand, is highly protein bound in plasma, but the unbound fraction shows high CNS penetration, with nearly all V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
CSF concentrations measured at random timepoints above the IC 50 . 11, 12 Although extensively studied in adult patients, paediatric data on CSF concentrations and CNS penetration of modern ARV drugs are lacking. It is particularly relevant in paediatric patients to investigate CNS characteristics of ARVs, as brain development is still ongoing and highly important in light of the increased survival of this population. Although BBB maturation has already taken place around the age of 1, it is unknown what the potential effect is of (perinatal) HIV on BBB maturation and functioning. 13, 14 The primary aim of this study was to evaluate the CNS ARV drug penetration and CSF drug concentrations in HIV-infected children. In a cross-sectional study, we evaluated ARV drug concentrations in paired CSF and peripheral blood samples in HIV-infected children on long-term suppressive cART. The secondary objective was to evaluate the possible association between CSF drug concentrations and neurocognitive function.
Methods

Participants
This study was performed from December 2012 until January 2014 in perinatally HIV-infected children between 8 and 18 years of age in the Emma Children's Hospital in Amsterdam as a substudy of the NOVICE study (neurological, visual and cognitive performance in HIV-infected children). This is a cross-sectional study comparing perinatally HIV-infected children with matched healthy controls. Exclusion criteria were chronic neurological diseases such as epilepsy, intracerebral neoplasms and psychiatric disorders. For this substudy, clinically stable, HIV-infected children on long-term cART were included in whom a lumbar puncture was performed to evaluate potential neurocognitive dysfunction. An additional CSF sample was obtained and stored at #70 C for the purpose of our study. A paired blood sample was collected in parallel with the CSF sample collection. Plasma was separated after centrifugation and stored at #70 C until further analysis. The HIV viral load in CSF and plasma was determined using the Abbott Real Time HIV-1 assay with a lower limit of quantification of ,40 copies/mL in plasma and ,150 copies/mL in CSF.
Ethics
The NOVICE study protocol was approved by the Ethics Committee of the Academic Medical Center in Amsterdam. Written informed consent was obtained from participants' parents or legal guardians, as well as from children .12 years of age. This study was registered with the Dutch Trial Register (Nederlands Trial Register) as NRT4074. 3 
ARV drug concentrations and penetration
ARV drug concentrations were analysed simultaneously using a validated method involving LC-MS (Shimadzu LC-30 Nexera system, NishinokyoKuwabaracho, Japan, coupled to an AB Sciex, Framingham, MA, USA, API5500Q LC-MS).
For CSF, the method was validated over a concentration range of 0.20-10 ng/mL for abacavir, 1.0-20 ng/mL for ritonavir and 0.10-20 ng/mL for the other compounds. Dilution series were used. For plasma, the method was validated over a range of 50-10 000 ng/mL for efavirenz and nevirapine, 100-5000 ng/mL for lopinavir and 10-2000 ng/mL for the other compounds. For both methods, accuracies ranged from 88.9% to 115.0%, the intra-day precision was ,11.0% and the inter-day precisions were ,15.3%. BBB permeability was assessed by calculating the CSF/plasma albumin ratio. CNS drug penetration for each drug was assessed by calculating the ARV drug CSF/plasma ratio. To adjust for ARV-to-protein binding in plasma, we calculated protein-free concentrations of ARVs by multiplying total plasma drug concentrations by the protein-unbound fraction (extracted from literature). 8, 15, 16 CSF concentrations of ARVs were compared with their IC 50 to evaluate effectiveness.
Neuropsychological assessment
Neuropsychological assessment was performed by a single neuropsychologist, described in detail before. 3 
Statistical analyses
All statistical analyses were performed using Stata Statistical Software (version 13.0; StataCorp, College Station, TX, USA). P , 0.05 was considered statistically significant. Correlations were assessed by using Spearman's rank correlation. Regression analyses were conducted to explore associations between CSF drug concentrations and neurocognitive outcome (total IQ). Owing to the restricted sample size, this was only conducted for the drugs lamivudine, abacavir and efavirenz. Total IQ and lamivudine were used as a continuous variable; efavirenz and abacavir were dichotomized using the IC 50 due to their non-normal distribution.
Results
A total of 22 children were initially included in this substudy (Table 1) . High (.95%) adherence to medication was self-reported by all study patients. All participants had an HIV viral load below the lower limit of quantification in both blood and CSF. The median time between plasma and CSF sampling was 10 (IQR 10-15) min. Time interval between the last cART dose and CSF sampling ranged from 2.7 to 19.3 h (Figure 1 ). Two children were excluded from further analysis; one based on an abnormally high CSF/plasma albumin ratio (.12), the other due to unreliable ARV measurements.
Plasma and CSF concentrations of different ARVs in the remaining 20 children are shown in Table 2 . Penetration of individual ARVs is shown in Figure 2 (protein uncorrected and corrected). Regarding drug effectiveness, CSF concentrations of tenofovir, lamivudine and emtricitabine did not reach the IC 50 in any of the cases. Abacavir did not reach the IC 50 in 50% and zidovudine did not reach the IC 50 in 17%. Lopinavir, efavirenz and nevirapine reached the IC 50 in all cases (Figure 3) .
No correlations were found between the ARV drug dose and CSF concentrations, and between ARV drug dose and CSF/plasma ratio (protein binding uncorrected and corrected). The interval between the last dose of abacavir and CSF sampling was strongly associated with the abacavir CSF concentration (rho " -0.948; P , 0.0001), but not with the CSF/plasma ratio of abacavir. The other ARVs did not show correlations between this interval and CSF concentration.
CSF and serum albumin measurements were available for 19 participants. The median BBB CSF/plasma albumin ratio was 0.003 (IQR 0.002-0.003) and was not associated with age (rho " 0.24, P " 0.31) or with the CSF/plasma ratio or CSF concentrations of the different ARVs.
Associations with neurocognitive functioning
Univariate linear regression analyses revealed no significant associations between CSF drug levels of efavirenz, lamivudine and abacavir and cognitive functioning, measured by total intelligence quotient (efavirenz: coefficient " 0.824, P " 0.641; lamivudine:
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Discussion
In this study, we evaluated ARV drug penetration into CNS in HIV-infected children on long-term cART. In our study population, CNS penetration was shown to be lower for tenofovir and lopinavir in comparison with the ARV drugs lamivudine, emtricitabine, nevirapine, zidovudine, abacavir and efavirenz. CNS drug concentrations of tenofovir and emtricitabine did not reach the drug-specific IC 50 in any of our study participants. Despite suboptimal CNS concentrations of individual drugs, all children in our study group were virologically suppressed in both blood and CSF. This suggests that although CSF concentrations of individual ARVs might have been potentially inadequate to suppress the virus, the use of a combination of ARVs prevented ongoing viral replication.
Tenofovir showed the lowest CNS penetration of all ARVs in our study, and did not reach adequate concentrations in CNS in any child. These outcomes were previously described in HIV-infected adult studies, in which CSF sampling was performed at various post-dose timepoints, including the timepoint just before the next dose (CSF trough concentration, or C trough ). 10, [17] [18] [19] The low drug lipophilicity of tenofovir and the presence of efflux transporters in the BBB might contribute to the potentially suboptimal results. 20 Emtricitabine did not reach adequate CSF concentrations in any of the three children in this paediatric study either. As the number of patients in our study on this drug was limited, broad conclusions on the workings of emtricitabine in children cannot be drawn. This restricts drawing broad conclusions to the population of children using emtricitabine. However, these data are in line with studies in HIV-infected adults, which consistently showed most CSF concentrations of emtricitabine to be below the IC 50 . 18, 19 Despite previously reported adequate CNS penetration of abacavir, it did not reach the IC 50 in half of the patients on abacavircontaining regimens. Specifically, those children that had a longer interval between last dosing and CSF sampling showed potentially suboptimal CSF abacavir concentrations, possibly due to the short extracellular half-life of abacavir. 21 Abacavir is frequently Van den Hof et al.
prescribed in children as it is part of the preferred dual NRTI backbone in first-line ART for infants and children, according to the WHO guidelines. 22 This implicates, according to our results, that the brain might be exposed to potentially suboptimal abacavir levels for a substantial period. These results are in contrast with the results of a study performed in adults, which predicted that 85% of the abacavir C trough concentrations would exceed the IC 50 based on pharmacokinetic modelling. 23 Another clinical study in adult patients showed that the median concentration of CSF abacavir measured was above the IC 50 , but this was only measured 1 h after drug administration. 24 Zidovudine reached the IC 50 in almost all patients (83%), which is in line with studies in adults performed at various timepoints after the last dose. 24, 25 CSF concentrations of lamivudine were all above the IC 50 . Compared with studies in adults, one reported all CSF concentrations to be above the IC 50 , but the IC 50 used was not mentioned. 25 Proper comparisons between studies are difficult to perform, as different IC 50 values have been reported in the literature (ranging from 0.46 to 549.6 ng/mL). 26, 27 Similar to what is reported in HIV-infected adults, ritonavirboosted lopinavir was shown to have CSF concentrations above the IC 50 in all patients. In the adult population, this was observed at various post-dose timepoints, including C trough concentration. CNS penetration of cART in children
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Despite optimal concentrations in CSF, CNS penetration in the adult population was considered quite low. This was most likely influenced by high protein binding of lopinavir, as only total drug concentrations were evaluated. 28, 29 The NNRTIs efavirenz and nevirapine were shown to have CSF concentrations above the IC 50 . Although this is comparable to earlier published data on adult patients, our data on nevirapine is based on measurements from only one patient and therefore broad conclusions cannot be drawn from these results. 11, 12, 24, 30, 31 No associations were found between CNS drug penetration, BBB permeability and age. This suggests that in our cohort of HIVinfected children, BBB function remained constant without measurable changes between the ages of 8 and 18 years. Moreover, no associations were found between CSF ARV drug concentrations of lamivudine, abacavir, efavirenz and neurocognitive functioning. However, the limited sample size should be taken into account when interpreting these results.
Despite generating important data on this understudied topic, this study has some important limitations. Paired blood plasma and CSF samples were obtained from children at various timepoints after the last cART dose, instead of obtaining standardized C trough measurements. This could have contributed relevant information about the lowest concentrations reached in CSF. However, the CSF concentrations of some ARVs may not vary greatly with time, e.g. efavirenz concentrations remained relatively stable in plasma and CSF over a 24 h dosing interval in one patient, probably due to its long half-life. 30 Another limitation of this study is the measurement of total ARV drug concentrations. Although protein binding in CSF is considered low, only protein-unbound ARVs are pharmacologically active. This is particularly important for NNRTIs and PIs, both of which are highly protein bound in plasma. In this study, correction for protein binding was performed using published data on ARV protein binding. Ideally, protein-unbound ARV concentrations should have been measured.
We observed a high degree of variability in drug concentration between subjects. Possible causes include differences in plasma protein binding properties of a specific drug, drug level measurement at various time intervals as related to medication intake and genetic polymorphisms in relevant enzymes and transporters. 32, 33 Although CSF sampling is the most adequate way to study drug concentrations in the CNS in a clinical setting, this remains an indirect method to describe active drug concentrations that are relevant at the site of the receptor within brain tissue. Even more so, NRTI drug concentrations in CSF do not reflect active drug concentrations, as they need to be phosphorylated intracellularly to become biologically active. 34 Moreover, we were restricted to a small sample size, as a lumbar puncture (for CSF collection) is an invasive investigation in children that was only performed in a subset of participants. Therefore, selection bias cannot be ruled out.
Lastly, CSF ARV concentrations were compared with the previously reported IC 50 of the WT virus. This may not adequately reflect the clinical setting of our patients where HIV is exposed to years of cART use and has potentially undergone (minimal) genetic change. In spite of these limitations, however, the use of the IC 50 is a practical and good method to objectify and compare drug concentrations.
In conclusion, we evaluated CSF penetration of ARV drugs in HIV-infected children between 8 and 18 years old on long-term cART, showing a potentially low CSF concentration of tenofovir, emtricitabine and abacavir. Despite these variable and potentially suboptimal concentrations of different ARVs, there were no signs of viral replication in the CSF and no associations with neurocognitive functioning.
